81 FR 11804 - Mechanistic Oral Absorption Modeling and Simulation for Formulation Development and Bioequivalence Evaluation; Public Workshop; Request for Comments

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Federal Register Volume 81, Issue 44 (March 7, 2016)

Page Range		11804-11806
FR Document		2016-04965

The Food and Drug Administration (FDA or the Agency) is announcing a public workshop entitled ``Mechanistic Oral Absorption Modeling and Simulation for Formulation Development and Bioequivalence Evaluation.'' The purposes of the workshop are to share current FDA experiences on the application of mechanism-based absorption modeling and simulation in regulatory activities; discuss current and future utility of mechanism-based absorption modeling and simulation in the development of bioequivalent oral drug products and regulatory reviews; obtain input from various stakeholders on when, where, and how to conduct mechanism-based absorption modeling and simulations in the context of bioequivalent product development; and request comments on these topics.

Federal Register, Volume 81 Issue 44 (Monday, March 7, 2016)

[Federal Register Volume 81, Number 44 (Monday, March 7, 2016)]
[Notices]
[Pages 11804-11806]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2016-04965]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2016-N-0668]


Mechanistic Oral Absorption Modeling and Simulation for 
Formulation Development and Bioequivalence Evaluation; Public Workshop; 
Request for Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public workshop; request for comments.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or the Agency) is

[[Page 11805]]

announcing a public workshop entitled ``Mechanistic Oral Absorption 
Modeling and Simulation for Formulation Development and Bioequivalence 
Evaluation.'' The purposes of the workshop are to share current FDA 
experiences on the application of mechanism-based absorption modeling 
and simulation in regulatory activities; discuss current and future 
utility of mechanism-based absorption modeling and simulation in the 
development of bioequivalent oral drug products and regulatory reviews; 
obtain input from various stakeholders on when, where, and how to 
conduct mechanism-based absorption modeling and simulations in the 
context of bioequivalent product development; and request comments on 
these topics.

DATES: The public workshop will be held on May 19, 2016, from 8:30 a.m. 
to 4:30 p.m. Individuals who wish to attend the workshop must register 
by April 19, 2016. The deadline for submitting either electronic or 
written comments on this workshop is June 20, 2016. See the 
SUPPLEMENTARY INFORMATION section for registration date and 
information.

ADDRESSES: The public workshop will be held at FDA White Oak Campus, 
10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room 
(Rm. 1503A), Silver Spring, MD 20993-0002. Entrance for the public 
workshop participants (non-FDA employees) is through Building 1, where 
routine security check procedures will be performed. For parking and 
security information, please refer to http://www.fda.gov/AboutFDA/WorkingatFDA/BuildingsandFacilities/WhiteOakCampusInformation/ucm241740.htm.
    You may submit comments as follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: http://www.regulations.gov. 
Follow the instructions for submitting comments. Comments submitted 
electronically, including attachments, to http://www.regulations.gov 
will be posted to the docket unchanged. Since your comment will be made 
public, you are solely responsible for ensuring that your comment does 
not include any confidential information that you or a third party may 
not wish to be posted, such as medical information, your or anyone 
else's Social Security number, or confidential business information, 
such as a manufacturing process. Please note that if you include your 
name, contact information, or other information that identifies you in 
the body of your comments, that information will be posted on http://www.regulations.gov.
     If you want to submit a comment with confidential 
information that you do not wish to be made available to the public, 
submit the comment as a written/paper submission and in the manner 
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand delivery/Courier (for written/paper 
submissions): Division of Dockets Management (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Division of 
Dockets Management, FDA will post your comment, as well as any 
attachments, except for information submitted, marked and identified, 
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No. 
FDA-2016-N-0668 for ``Mechanistic Oral Absorption Modeling and 
Simulation for Formulation Development and Bioequivalence Evaluation; 
Public Workshop; Request for Comments.'' Received comments will be 
placed in the docket and, except for those submitted as ``Confidential 
Submissions,'' publicly viewable at http://www.regulations.gov or at 
the Division of Dockets Management between 9 a.m. and 4 p.m., Monday 
through Friday.
     Confidential Submissions--To submit a comment with 
confidential information that you do not wish to be made publicly 
available, submit your comments only as a written/paper submission. You 
should submit two copies total. One copy will include the information 
you claim to be confidential with a heading or cover note that states 
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will 
review this copy, including the claimed confidential information, in 
its consideration of comments. The second copy, which will have the 
claimed confidential information redacted/blacked out, will be 
available for public viewing and posted on http://www.regulations.gov. 
Submit both copies to the Division of Dockets Management. If you do not 
wish your name and contact information to be made publicly available, 
you can provide this information on the cover sheet and not in the body 
of your comments and you must identify this information as 
``confidential.'' Any information marked as ``confidential'' will not 
be disclosed except in accordance with 21 CFR 10.20 and other 
applicable disclosure law. For more information about FDA's posting of 
comments to public dockets, see 80 FR 56469, September 18, 2015, or 
access the information at: http://www.fda.gov/regulatoryinformation/dockets/default.htm.
    Docket: For access to the docket to read background documents or 
the electronic and written/paper comments received, go to http://www.regulations.gov and insert the docket number, found in brackets in 
the heading of this document, into the ``Search'' box and follow the 
prompts and/or go to the Division of Dockets Management, 5630 Fishers 
Lane, Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Xinyuan Zhang, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 75, Rm. 4612, Silver Spring, MD 20993, 240-402-
7971, email: [email protected]; or Liang Zhao, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 75, Rm. 4606, Silver Spring, MD 20993, 240-402-
4468, email: [email protected].

SUPPLEMENTARY INFORMATION:

I. Background

    In July 2012, Congress passed the Generic Drug User Fee Amendments 
(GDUFA) (Title III of the Food and Drug Administration Safety and 
Innovation Act (Pub. L. 112-144)). GDUFA is designed to enhance public 
access to safe, high-quality generic drugs and reduce costs to 
industry. To support this goal, FDA agreed in the GDUFA commitment 
letter to work with industry and interested stakeholders on identifying 
regulatory science research priorities specific to generic drugs for 
each fiscal year covered by GDUFA. The commitment letter outlines FDA's 
performance goals and procedures under the GDUFA program for the years 
2012 to 2017. The commitment letter can be found at http://www.fda.gov/downloads/ForIndustry/UserFees/GenericDrugUserFees/UCM282505.pdf.
    In the Regulatory Science section of the GDUFA Commitment Letter, 
FDA outlined its plans to advance regulatory science, including with 
respect to modeling and simulation. To enhance communication of recent 
advances in modeling and simulation, including those supported by GDUFA 
funds, FDA plans to hold a public workshop on

[[Page 11806]]

mechanistic oral absorption modeling and simulation. Mechanism-based 
absorption modeling and simulation is a computational tool that 
integrates drug substance information, drug product information, drug 
product in vitro performance, and physiological properties of the human 
body to predict drug product pharmacokinetics in vivo. Modeling 
simulation studies may also, in principle, be used as a tool to 
elucidate dissolution boundaries that have high likelihood of remaining 
bioequivalence, and those boundaries can be used to inform clinically 
relevant dissolution specifications. Models developed in a mechanistic 
manner integrating all available knowledge relevant to the absorption 
process lend great value for development of bioequivalent oral drug 
products and regulatory evaluation because the main differences between 
the reference drug products and the bioequivalent products (e.g., the 
difference in formulation factors) are taken into account in the model.

II. Purpose and Scope of the Workshop

    The purpose of the workshop is to:
    1. Share FDA's current experiences on the application of mechanism-
based absorption modeling and simulation in regulatory activities;
    2. Discuss the current and future utility of mechanism-based 
absorption modeling and simulation in development of bioequivalent oral 
drug products and regulatory reviews; and
    3. Obtain input from the public on when, where, and how mechanism-
based absorption modeling and simulation should be applied in 
development of bioequivalent oral drug products and review of 
bioequivalence.
    The scope of the workshop covers the current status of mechanism-
based absorption modeling and simulation from academia, industry, and 
regulatory perspectives.
    The majority of drug products on the market are administered 
orally. Predicting oral bioavailability is always of great interest for 
pharmaceutical scientists. It has been a long journey for scientists to 
develop mechanistic absorption models for oral bioavailability 
prediction to reduce drug development time and cost, and to inform 
regulatory decisions. From simpler models to more complex ones, 
mechanism-based absorption models have been advanced substantially and 
their applications have been increasingly found in scientific 
literature and regulatory reports.
    The high value of leveraging mechanistic absorption models in the 
development and evaluation of bioequivalent drug products can be 
attributed to their incorporation of formulation factors. The focus of 
this public workshop is on the application of mechanistic absorption 
modeling and simulation for development of bioequivalent oral drug 
products and evaluation of bioequivalence, including discussing the 
areas in which mechanistic oral absorption models can contribute 
significantly, how the mechanistic absorption modeling and simulation 
should be conducted and evaluated, and inherent scientific challenges.
    Public input will improve FDA's current understanding of using 
mechanism-based absorption modeling and simulation in bioequivalence 
evaluation. The knowledge gained from, and consensus reached, through 
this workshop will be summarized and disseminated to the scientific 
community by publication(s).

III. Scope of Public Input Requested

    FDA seeks input from the public on when, where, and how to utilize 
mechanism-based absorption modeling and simulation in the context of 
development of bioequivalent oral drug products and regulatory 
evaluation of bioequivalence. Specific topics to be addressed include:
    1. Identifying the areas in which mechanistic oral absorption 
models can contribute significantly during development of bioequivalent 
oral drug products and regulatory evaluation of bioequivalence;
    2. How mechanistic absorption modeling and simulation should be 
conducted and evaluated; and
    3. The scientific challenges in mechanistic oral absorption and 
simulation.
    Registration and Requests for Attendee Participation: The FDA 
Conference Center at the White Oak Campus is a Federal facility with 
security screening and limited seating. Individuals who wish to attend 
the public workshop (either in person or by Webcast (see Streaming 
Webcast of the Public Workshop)) must register on or before April 19, 
2016, by sending a request to [email protected] with their 
complete contact information (i.e., name, title, affiliation, address, 
email address, and telephone number).
    There is no registration fee for the public workshop. Early 
registration is recommended because seating is limited. Registration on 
the day of the public workshop will be provided on a space available 
basis beginning at 8 a.m.
    If you need special accommodations due to a disability, please 
contact Xinyuan Zhang (see FOR FURTHER INFORMATION CONTACT) at least 7 
days in advance.
    The workshop agenda and other background materials will be 
available approximately 2 weeks before the workshop at http://www.fda.gov/Drugs/NewsEvents/ucm488178.htm. The agenda will include 
time for questions and answers throughout the day and for general 
comments and questions from the audience following panel discussions.
    In this document, FDA has included specific issues that will be 
addressed by the panel. If you wish to address one or more of these 
issues, please submit your comments via the Docket or speak during the 
public comments session at the workshop. If you wish to speak during 
the public comments session at the workshop, please indicate it at the 
time you register so that FDA can consider that in planning the agenda. 
FDA will do its best to accommodate requests to speak.
    Streaming Webcast of the Public Workshop: A live Webcast of this 
workshop will be viewable at https://collaboration.fda.gov/r6gjahu3ejv 
on the day of the workshop. The live Webcast will be in a listening 
only mode.
    Transcripts: Transcripts of the workshop will be available for 
review at http://www.fda.gov/Drugs/NewsEvents/ucm488178.htm at the 
Division of Dockets Management (see ADDRESSES), and at http://www.regulations.gov approximately 30 days after the workshop. A 
transcript will also be available, in either hardcopy or on CD-ROM, 
after submission of a Freedom of Information request. The Freedom of 
Information office address is available on the Agency's Web site at 
http://www.fda.gov.

    Dated: March 1, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016-04965 Filed 3-4-16; 8:45 am]
BILLING CODE 4164-01-P

11804 Federal Register / Vol. 81, No. 44 / Monday, March 7, 2016 / Notices

information to: kristie.kulinski@ 2015, Pub. L. 113–235, Div. G., Title information listed below has been
acl.hhs.gov. Submit written comments II, 219(a); and the Patient Protection and submitted to the Office of Management
on the collection of information to Affordable Care Act, 42 U.S.C. 300u–11 and Budget (OMB) for review and
Kristie Kulinski, U.S. Administration for (Prevention and Public Health Fund). clearance under the Paperwork
Community Living, Administration on OMB approval of the existing set of Reduction Act of 1995.
Aging, 330 C Street SW., Washington, CDSME data collection tools (OMB DATES: Submit written comments on the
DC 20230. Control Number, 0985–0036) expires on collection of information by May 6,
FOR FURTHER INFORMATION CONTACT: 07/31/2016. This data collection 2016.
Kristie Kulinski (kristie.kulinski@ continues to be necessary for monitoring
ADDRESSES: Submit written comments
acl.hhs.gov). program operations and outcomes. ACL
on the collection of information by fax
SUPPLEMENTARY INFORMATION: Under the
proposes to use revised versions of the
202–395–5806 or by email to OIRA_
PRA (44 U.S.C. 3501–3520), Federal following tools: (1) Semi-annual
submission@omb.eop.gov, Attn: OMB
agencies must obtain approval from the progress reports to monitor grantee
Desk Officer for ACL.
Office of Management and Budget progress; (2) an Organization Data form
to record location of sites where FOR FURTHER INFORMATION CONTACT:
(OMB) for each collection of Phillip McKoy at 202–795–7397 or
information they conduct or sponsor. programs are held which will allow
mapping of the delivery infrastructure; email: phillip.mckoy@acl.hhs.gov.
‘‘Collection of information’’ is defined SUPPLEMENTARY INFORMATION: In
in 44 U.S.C. 3502(3) and 5 CFR and (3) a set of tools used to collect
information at each program completed compliance with 44 U.S.C. 3507, ACL
1320.3(c) and includes agency request has submitted the following proposed
or requirements that members of the by the program leaders/delivery
personnel (Program Information Cover collection of information to OMB for
public submit reports, keep records, or review and clearance.
provide information to a third party. Sheet and Attendance Log) and a
Participant Information Survey Grantees are required by Congress to
Section 3506(c)(2)(A) of the PRA (44 provide information for use in program
U.S.C. 3506(c)(2)(A)) requires Federal completed by each participant to
document their demographic and health monitoring and for Government
agencies to provide a 60-day notice in Performance and Results Act (GPRA)
the Federal Register concerning each characteristics. ACL is not requesting
renewal of one other data collection purposes. This information collection
proposed collection of information, reports the number of active volunteers,
including each proposed extension of an tool, the Annual Integrated Services
Delivery System Assessment Tool. ACL issues and inquiries received, other
existing collection of information, SMP program outreach activities, and
before submitting the collection to OMB proposes to gather data using an existing
online data entry system for the program the number of Medicare dollars
for approval. To comply with this recovered, among other SMP
requirement, AoA is publishing notice and participant survey data. The current
proposed Data Collection Tools can be performance outcomes. This
of the proposed collection of information is used as the primary
information set forth in this document. found at ACL’s Web site at: http://
www.aoa.acl.gov/AoA_Programs/Tools_ method for monitoring the SMP
With respect to the following collection Projects.
of information, ACL invites comments Resources/collection_tools.aspx. ACL
estimates the burden of this collection ACL estimates the burden of this
on: (1) Whether the proposed collection collection of information as follows:
of information is necessary for the of information as 128 hours for grantee
staff, 220 hours for local agency staff Respondents: 54 SMP grantees at 23
proper performance of ACL’s functions, hours per month (276 hours per year,
including whether the information will and volunteers, and 92 hours for
individuals—Total burden is 440 hours per grantee). Total Estimated Burden
have practical utility; (2) the accuracy of Hours: 7,452 hours per year.
ACL’s estimate of the burden of the per year. This assumes a data collection
proposed collection of information, sample of 386 workshops. Dated: March 1, 2016.
including the validity of the Dated: March 1, 2016. Kathy Greenlee,
methodology and assumptions used; (3) Kathy Greenlee, Administrator and Assistant Secretary for
ways to enhance the quality, utility, and Aging.
Administrator and Assistant Secretary for
clarity of the information to be Aging. [FR Doc. 2016–04925 Filed 3–4–16; 8:45 am]
collected; and (4) ways to minimize the [FR Doc. 2016–04924 Filed 3–4–16; 8:45 am] BILLING CODE 4154–01–P
burden of the collection of information BILLING CODE 4154 –01–P
on respondents, including through the
use of automated collection techniques DEPARTMENT OF HEALTH AND
when appropriate, and other forms of DEPARTMENT OF HEALTH AND HUMAN SERVICES
information technology. The HUMAN SERVICES Food and Drug Administration
‘‘Empowering Older Adults and Adults
with Disabilities through Chronic Administration for Community Living [Docket No. FDA–2016–N–0668]
Disease Self-Management Education
(CDSME) Programs’’ cooperative Agency Information Collection Mechanistic Oral Absorption Modeling
agreement program has been financed Activities; Submission for OMB and Simulation for Formulation
through Prevention and Public Health Review; Comment Request; Senior Development and Bioequivalence
Funds (PPHF), most recently by FY2015 Medicare Patrol (SMP) Program Evaluation; Public Workshop; Request
asabaliauskas on DSK3SPTVN1PROD with NOTICES

PPHF funds. The statutory authority for Outcome Measurement for Comments
cooperative agreements under the AGENCY: Administration for Community AGENCY: Food and Drug Administration,
current program announcement is Living, HHS. HHS.
contained in the Public Health Service ACTION: Notice. ACTION: Notice of public workshop;
Act, 42 U.S.C. 300u–2 (Community request for comments.
Programs) and 300u–3 (Information SUMMARY: The Administration for
Programs); and Consolidated and Community Living (ACL) is announcing SUMMARY: The Food and Drug
Further Continuing Appropriations Act, that the proposed collection of Administration (FDA or the Agency) is

VerDate Sep<11>2014 18:37 Mar 04, 2016 Jkt 238001 PO 00000 Frm 00067 Fmt 4703 Sfmt 4703 E:\FR\FM\07MRN1.SGM 07MRN1

Document Created: 2018-02-02 15:07:46
Document Modified: 2018-02-02 15:07:46

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Action		Notice of public workshop; request for comments.
Dates		The public workshop will be held on May 19, 2016, from 8:30 a.m. to 4:30 p.m. Individuals who wish to attend the workshop must register by April 19, 2016. The deadline for submitting either electronic or written comments on this workshop is June 20, 2016. See the SUPPLEMENTARY INFORMATION section for registration date and information.
Contact		Xinyuan Zhang, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 4612, Silver Spring, MD 20993, 240-402- 7971, email: [email protected]; or Liang Zhao, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 4606, Silver Spring, MD 20993, 240-402- 4468, email: [email protected]
FR Citation		81 FR 11804

81 FR 11804 - Mechanistic Oral Absorption Modeling and Simulation for Formulation Development and Bioequivalence Evaluation; Public Workshop; Request for Comments

DEPARTMENT OF HEALTH AND HUMAN SERVICESFood and Drug Administration

Federal Register Volume 81, Issue 44 (March 7, 2016)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration